© 2003 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2003 Oxford University Press
NEWS |
More States Mandate Coverage of Clinical Trial Costs, But Does It Make a Difference?
| The first 10% of the full text of this article appears below. |
In the last few years, a number of states have enacted legislation aimed at increasing the accrual of patients into cancer clinical trials. Beginning in 2000, 13 states enacted laws mandating that managed care and individual and group insurers cover most routine medical care associated with participation in cancer clinical trials. That is in addition to the six states that already had such laws on the books; Rhode Island was the first in 1994 (see Stat Bite, p. 1269).
Instead of a law, New Jersey in late 1999 achieved a consensus agreement whereby all insurance companies operating in the state agreed to basic tenets regarding reimbursement for patient participation in government-funded phase I, II, and III cancer clinical trials. Michigan also has a cooperative agreement among insurers
Rhode Island
California